Oculis Holding AG (OCS)Healthcare | Biotechnology | Zug, Switzerland | NasdaqGM
27.46 USD
+0.09
(0.329%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 27.46 Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 1:24 p.m. EDT
Strong analyst buy consensus clashes with weak fundamentals, but options flow and recent price action suggest a slight short-term upside lean with potential for moderate gains. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.103848 |
| AutoETS | 0.447616 |
| AutoARIMA | 0.450184 |
| MSTL | 0.569661 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 65.42 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.129 |
| Excess Kurtosis | -1.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.18 |
| Revenue per Share | 0.023 |
| Market Cap | 1,592,252,672 |
| Forward P/E | -12.89 |
| Beta | 0.21 |
| Website | https://oculis.com |
As of April 18, 2026, 1:24 p.m. EDT: Calls show strong ATM (25.0) and higher strike (30.0, 40.0) positioning with elevated IV, suggesting bullish bias. Puts have limited activity, but higher IV at 25.0 strike indicates cautiousness. New flow in 40.0 call (45.7% OTM) hints at long-term optimism, while short-term momentum remains neutral.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5154525 |
| Address1 | Bahnhofstrasse 20 |
| All Time High | 30.68 |
| All Time Low | 6.26 |
| Ask | 27.67 |
| Ask Size | 1 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 179,090 |
| Average Daily Volume3 Month | 317,448 |
| Average Volume | 317,448 |
| Average Volume10Days | 179,090 |
| Beta | 0.208 |
| Bid | 27.31 |
| Bid Size | 1 |
| Book Value | 4.316624 |
| City | Zug |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 27.46 |
| Current Ratio | 5.957 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 27.705 |
| Day Low | 26.883 |
| Debt To Equity | 1.18 |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -81,520,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -16.947 |
| Enterprise To Revenue | 1,152.254 |
| Enterprise Value | 1,381,552,640 |
| Eps Current Year | -1.74646 |
| Eps Forward | -2.1307416 |
| Eps Trailing Twelve Months | -2.42 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 27.3065 |
| Fifty Day Average Change | 0.1534996 |
| Fifty Day Average Change Percent | 0.005621358 |
| Fifty Two Week Change Percent | 51.54525 |
| Fifty Two Week High | 30.68 |
| Fifty Two Week High Change | -3.2200012 |
| Fifty Two Week High Change Percent | -0.10495441 |
| Fifty Two Week Low | 16.0 |
| Fifty Two Week Low Change | 11.459999 |
| Fifty Two Week Low Change Percent | 0.71624994 |
| Fifty Two Week Range | 16.0 - 30.68 |
| Financial Currency | CHF |
| First Trade Date Milliseconds | 1,621,344,600,000 |
| Float Shares | 49,970,409 |
| Forward Eps | -2.1307416 |
| Forward P E | -12.887531 |
| Free Cashflow | -43,680,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 60 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -55,886,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04271 |
| Held Percent Institutions | 0.52602 |
| Implied Shares Outstanding | 57,984,438 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-03-03 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland. |
| Long Name | Oculis Holding AG |
| Market | us_market |
| Market Cap | 1,592,252,672 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_589165623 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -98,957,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,592,252,667 |
| Number Of Analyst Opinions | 10 |
| Open | 27.48 |
| Operating Cashflow | -66,304,000 |
| Operating Margins | -50.20195 |
| Payout Ratio | 0.0 |
| Phone | 41 41 711 3960 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 27.46 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 27.37 |
| Price Eps Current Year | -15.723234 |
| Price Hint | 2 |
| Price To Book | 6.3614526 |
| Price To Sales Trailing12 Months | 1,327.9839 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.846 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | 0.0899982 |
| Regular Market Change Percent | 0.328821 |
| Regular Market Day High | 27.705 |
| Regular Market Day Low | 26.883 |
| Regular Market Day Range | 26.883 - 27.705 |
| Regular Market Open | 27.48 |
| Regular Market Previous Close | 27.37 |
| Regular Market Price | 27.46 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 366,045 |
| Return On Assets | -0.28652 |
| Return On Equity | -0.7345 |
| Revenue Growth | 136.0 |
| Revenue Per Share | 0.023 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 57,984,438 |
| Shares Percent Shares Out | 0.0082 |
| Shares Short | 473,925 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 623,971 |
| Short Name | Oculis Holding AG |
| Short Percent Of Float | 0.0095 |
| Short Ratio | 1.29 |
| Source Interval | 15 |
| Symbol | OCS |
| Target High Price | 56.42812 |
| Target Low Price | 38.097557 |
| Target Mean Price | 47.922676 |
| Target Median Price | 49.451416 |
| Total Cash | 213,012,992 |
| Total Cash Per Share | 3.674 |
| Total Debt | 2,313,000 |
| Total Revenue | 1,199,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.42 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.6777 |
| Two Hundred Day Average Change | 5.782299 |
| Two Hundred Day Average Change Percent | 0.26673952 |
| Type Disp | Equity |
| Volume | 366,045 |
| Website | https://oculis.com |
| Zip | 6,300 |